DENTSPLY SIRONA (XRAY) awards stock options and RSUs to SVP CHRO

Rhea-AI Filing Summary

Frohning Andrea L. reported acquisition or exercise transactions in this Form 4 filing.

DENTSPLY SIRONA Inc. reported that SVP and CHRO Andrea L. Frohning received equity awards on March 4, 2026. She was granted stock options for 121,600 shares and an award of 26,786 restricted stock units, both vesting in equal one-third installments annually through March 4, 2029.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frohning Andrea L.

(Last) (First) (Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE NC 28277

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHRO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		26,786(1)	A	$0	63,992.252	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.78	03/04/2026		A		121,600		03/04/2027(2)	03/04/2036	Common Stock	121,600	$0	121,600	D

Explanation of Responses:

1. Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029.

2. Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 110% of the closing price of the Issuer's common stock as of the date of grant.

	/s/ Jessica Nielsen Causey, Attorney-in-Fact for Andrea Frohning	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards did DENTSPLY SIRONA (XRAY) report for Andrea L. Frohning?

Andrea L. Frohning received stock options covering 121,600 shares and an award of 26,786 restricted stock units. Both awards were granted on March 4, 2026 and represent non-cash equity compensation from DENTSPLY SIRONA Inc. to its SVP and CHRO.

How do the new stock options for Andrea L. Frohning at DENTSPLY SIRONA (XRAY) vest?

The stock options vest in annual one-third installments over three years, ending March 4, 2029. The exercise price equals 110% of the closing price of DENTSPLY SIRONA common stock on the grant date, aligning the award’s value with future share performance.

What are the vesting terms for the restricted stock units granted to Andrea L. Frohning at XRAY?

The restricted stock units vest in annual one-third increments over a three-year period ending March 4, 2029. This structure ties the full value of the 26,786-unit award to continued service and long-term alignment with DENTSPLY SIRONA shareholders.

How many DENTSPLY SIRONA (XRAY) common shares does Andrea L. Frohning hold after these transactions?

After the March 4, 2026 equity grants, Andrea L. Frohning directly holds 63,992.252 shares of DENTSPLY SIRONA common stock. This figure reflects her total direct non-derivative common stock ownership following the reported award acquisition transaction.

Were the reported DENTSPLY SIRONA (XRAY) insider transactions open-market purchases or sales?

The transactions were equity award acquisitions, not open-market buys or sells. Both the stock options and the restricted stock units were granted to Andrea L. Frohning as compensation, with no cash purchase price reported for the acquired securities.

What role does Andrea L. Frohning hold at DENTSPLY SIRONA (XRAY) in this Form 4 filing?

Andrea L. Frohning is identified as an officer of DENTSPLY SIRONA Inc., serving as Senior Vice President and Chief Human Resources Officer. The Form 4 reflects equity compensation granted to her in that executive capacity on March 4, 2026.